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procedures in the studies reviewed made it difficult to compare disease 
epidemiology across studies/countries, and understand disease trends overtime. 
Data suggested that the majority of hypogonadal individuals in the general 
population currently receive no treatment for the condition. Future studies 
should use consistent, internationally-accepted diagnostic criteria to define 
hypogonadism.  
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OBJECTIVES: To determine and compare the prevalence of use of anti-diabetic 
and antilipidemic medications in children and adolescents treated with atypical 
antipsychotics to those not treated with atypical antipsychotics. METHODS: 
Virginia Medicaid beneficiaries (between 2 and 17 years) continuously enrolled 
from August 1, 2010 to July 31, 2011 were included in the study. Subjects with at 
least two paid prescription claims for aripiprazole, olanzapine, quetiapine, 
risperidone, or ziprasidone were assigned to the exposed group. All other 
subjects in the Virginia Medicaid system during the study period were assigned 
to the non-exposed group. Prevalence of anti-diabetic and antilipidemic 
medication use in both groups were computed and compared using Chi-square 
test (α=0.05). Generic Code Numbers were used to identify all medications. 
RESULTS: A total of 299,593 patients (2,286,629 claims) were identified as  
the non-exposed group (mean age: 8.23 +/- 4.70 years, 50.10% males). Of these 
patients, 0.32% had prescription claims for anti-diabetic medications (mean  
age: 13.82 +/- 2.67 years, 28.42% males), and 0.087% had prescription claims  
for antilipidemic medications (mean age: 11.82 +/- 4.93 years, 55.94% males).  
A total of 5,663 patients had 53,236 claims for atypical antipsychotic agents 
(mean age: 12.02 +/- 3.63 years, 63.13% males). In this group 1.66% had 
prescription claims for anti-diabetic medications, and 0.37% had prescription 
claims for antilipidemic medications. There was a significantly higher rate of 
anti-diabetic and antilipidemic drug use in the exposed group compared with the 
non-exposed group (p<0.0001). Among the atypical anti-psychotic users, the 
highest number of claims was for risperidone (50.98%). The prevalence of 
antidiabetic medication claims was highest for ziprasidone (7.53%) and the 
prevalence of antilipidemic medications was highest for olanzapine (1.45%). 
CONCLUSIONS: The prevalence of anti-diabetic and antilipidemic medication 
use was higher among children and adolescents in the Virginia Medicaid 
population prescribed atypical antipsychotics than those not prescribed atypical 
antipsychotics.  
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OBJECTIVES: Qatar is one of the highest GDP in the world so the health care 
facility has high quality. But the men powers or technical skills have been 
underdeveloped compared to the similar GDP status countries. In addition, due 
to the peculiarity of culture and religion, the social activities of women are 
prohibited. These characters can effect on the burden of disease of Qatar. So in 
this study, We calculate the burden of disease then increase the international 
comparability. METHODS: Qatar has had no social insurance or medical 
insurance so our research team could get the mortality data and the inpatients 
data from the national hospitals in Qatar and the national community health 
research. Using the data, we calculated DALYs of Qatar. But in the case of visiting 
the primary health care center or outpatients, they didn’t use ICD code for the 
recording disease diagnosis. So there was some limitations regarding medical 
record data application. Qatar used ICD-9 code for their disease diagnosis then 
we converted to ICD-10 code then calculated DALYs. We used Dismod-II for 
estimating the age of onset and the illness of duration. For the disease disability, 
we applied disability weight of WHO. RESULTS: The most burden diseases in 
Qatar were perinatal diseases. Major 5 diseases among top 15 diseases were 
perinatal related diseases. Especially, asphyxia and birth trauma which were 
appeared during labor were the highest burden of diseases of 
women(9.02DALY/100,000 persons). CONCLUSIONS: The burden of diseases of 
Qatar was likely to developing country even though their high GDP. That is, the 
burden of perinatal diseases was higher but the burden of chronic diseases was 
lower. Especially, compare to other developed countries, the burden of abortion 
was high. It meant that the cultural specialties like a favoritism of boy was 
reflected. These kinds of diseases(like perinatal diseases) could decrease training 
people as obstetric professions.  
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OBJECTIVES: Testosterone replacement therapy is a widespread and growing 
practice for treating androgen deficiency. Many patients with androgen 
deficiency however remain untreated. The purpose of this study is to investigate 
the factors associated with testosterone therapy in aging males. METHODS: We 
identified patients with androgen deficiency based on ICD-9-CM diagnosis codes 
between January 1999 and December 2010 in Kaiser Permanente Southern 
California. The first diagnosis date was labeled as the index date. We excluded 
patients with: 1) age <45, 2) genetic indications for testosterone, 3) hypothalamic 
or pituitary dysfunction, 4) testicular, pituitary or prostate cancer, and 5) a 
testosterone prescription in the prior 12 months. Twelve months continuous 
membership before the index date was required for inclusion in the cohort. 
Multivariate logistic regression was used to identify factors (demographics, 
baseline testosterone levels and prostate-specific antigen levels [PSA], baseline 
comorbidity, and medication usage, physician characteristics and other health 
care system factors) associated with testosterone initiation. RESULTS: Among 
the identified patients (N=8,261), 33% (N=2,706) initiated testosterone within one 
year following the index date. Patient level factors significantly associated with 
testosterone treatment included younger age (odds ratio (OR)=1.37, 95% CI: 1.19-
1.57 for age 45-54 vs. 65-74), white race (OR=1.34 ,1.12-1.60 for white vs. black), 
low baseline testosterone level (OR=1.86, 1.61-2.15 for testosterone <200 vs. >300 
ng/dL), and low baseline PSA level (OR=1.38, 1.08-1.77 for PSA <4 vs. ≥4 ng/dL). 
Health care system factors significantly associated with treatment initiation: 
younger physician age (OR=1.26, 1.10-1.44 for age ≤40 vs. 51-60), male physician 
gender (OR=1.19, 1.05-1.36 for male vs. female), urology physician specialty 
(OR=1.41, 1.12-1.78 for urology vs. family medicine), health care facility location 
and year of the diagnosis. CONCLUSIONS: Patient and health care system factors 
were significantly associated with initiation of testosterone treatment. Future 
studies should evaluate age and racial differences in addition to health system 
factors.  
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OBJECTIVES: In Canada, approximately 25% of all births are delivered via 
cesarean section and this rate continues to rise. C-sections are associated with 
up to 20 times the surgical site infection (SSI) incidence rate as compared to 
vaginal births. A recent Canadian prospective trial assessing SSI in women after 
c-section found the incidence rate to be 7%. This study was conducted to 
determine the budget impact of incorporating the use of 2-Octyl cyanoacrylate in 
Canadian hospitals as an anti-microbial topical skin adhesive after c-section. 
METHODS: Clinical and economic data was obtained from peer-reviewed 
literature and through case-costing data from a large Canadian hospital. The 
efficacy data used to demonstrate a reduction in SSIs from the use of 2-Octyl 
cyanoacrylate was obtained through a large retrospective trial. One and two way 
sensitivity analyses were conducted on economic and clinical parameters to 
ensure robustness. RESULTS: Incorporating 2-Octyl cyanoacrylate use as an anti-
microbial tissue sealant after c-section has been found to reduce the incidence of 
SSI from 7.0% to 3.01%. Based on model calculations a hospital that completes a 
total of 500 c-sections per year would see 35 of its patients develop a SSI using 
standard preventative strategies. By incorporating the use of 2-Octyl 
cyanoacrylate into the standard of care the same hospital would see 
approximately 15 SSIs in the same patient population, for a total reduction of 20 
SSIs. Treatment costs for SSI vary greatly dependent on whether the infection is 
superficial or deep/organ space. Taking this into account, the model establishes 
that the use of 2-Octyl cyanoacrylate has the potential to provide a yearly net 
cost savings of $232, 660.00 when compared to the use of standard wound 
closure products. CONCLUSIONS: 2-Octyl cyanoacrylate is an anti-microbial 
tissue sealant that can be used cost-effectively post c-section in Canadian 
hospitals.  
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OBJECTIVES: Contraceptive methods vary by effectiveness, duration of effect and 
product-related costs. Consideration of both product- and unintended pregnancy 
(UP)-related costs over the full duration of effect is vital when health care payers 
make contraceptive coverage decisions. This analysis aimed to estimate the 
medical and pharmacy budget impact to a US health care plan when switching 
women from short-acting reversible contraceptives (SARC) to a low-dose 
levonorgestrel intrauterine system (LNG-IUS-12). METHODS: A three-year budget 
impact model was developed to estimate costs before and after availability of 
LNG-IUS-12, among women aged 15-44 years, at risk of UP, and covered by a US 
health care plan. US Census and National Survey of Family Growth determined 
current contraceptive usage. Pregnancy outcomes and failure rates were 
estimated using published literature. The model considered costs of 
contraceptives derived from Wolters Kluwers Health-MediSpan Master Drug 
Database, physician visits from Medicare Reimbursement Rate and pregnancy 
outcomes (live birth, induced or spontaneous abortion, and ectopic pregnancy) 
from the Health Care Utilization Project. Consistent with the Health and Human 
Services mandate on preventive services, no patient co-pay, co-insurance, or 
deductible was factored into this analysis. LNG-IUS-12 was assumed to gain 
0.5%, 0.3% and 0.2% market share from SARC methods in years 1, 2 and 3 
respectively, resulting in a target cumulative 1% uptake of the contraceptive 
market by year 3. A potential 20% discontinuation rate for LNG-IUS-12 in the 1st 
